The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
News|Podcasts|June 27, 2024
Innovation Series: A stem cell patch for treating advanced dry AMD
Author(s)Sheryl Stevenson
In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, about the progress made by a team of USC researchers on a novel stem cell patch for treating advanced dry age-related macular degeneration.
Advertisement
Advertisement
In this Ophthalmology Times EyePod podcast, Mandeep S. Singh, MD, PhD, speaks with Mark S. Humayun, MD, PhD, to learn about the advancements for a novel stem cell patch developed by a team of researchers at USC for the treatment of advanced dry age-related macular degeneration.
Related to this article
Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.
In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Advertisement
Advertisement